Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "AstraZeneca"


25 mentions found


Rumours of airlines discussing a potential ban on vaccinated passengers due to blood clot risks appear to be baseless. “IATA is not aware of any airlines considering denying vaccinated passengers due to the blood clot risk,” Anaelle Ashong, Corporate Communications Assistant at IATA (www.iata.org/en/about/) told Reuters via email. However, flying is not known to increase the vaccine-induced blood clot risk as flying can provoke a different type of blood clot, according to several health experts contacted by Reuters. There is no evidence that airlines met to discuss the blood clot risk for vaccinated passengers. Several medical experts told Reuters there is no evidence to show that flying increases vaccine-induced blood clot risk.
Persons: Anaelle, , Sue Pavord, Haematologist, ” Dr Gregory Poland, Read Organizations: International Air Transport Association, Reuters, “ Airlines, Johnson, AstraZeneca, Corporate Communications, U.S . Centers for Disease Control, Prevention, CDC, Oxford University Hospitals, British Society, Haematology, Mayo
Most of those currently in hospital with COVID-19 in Britain are unvaccinated, health officials say. The picture looks similar in North America, where hospitals have reported that the majority of their COVID-19 patients are unvaccinated (here , here , here). Preliminary data from a study at Cleveland Clinic, Ohio, found that most people hospitalised for coronavirus weren’t fully vaccinated. Of those patients, 99% were not fully vaccinated,” Eduardo Mireles, director of the medical intensive care unit, said in a statement released by the hospital (here). Unvaccinated people are much more vulnerable to catching - and becoming seriously ill from - COVID-19.
Persons: Johnson, Chris Hopson, India –, coronavirus weren’t, we’ve, ” Eduardo Mireles, Read Organizations: Pfizer, Oxford, AstraZeneca, Moderna, NHS, Cleveland Clinic, Reuters Locations: Britain, COVID, Moderna, Bolton –, India, North America, Cleveland Clinic , Ohio
Social media users have made unfounded claims to cast doubt over the authenticity of the Duchess of Cambridge’s COVID-19 vaccination. Alongside a screenshot of a news report with the image, one Instagram user wrote: “A fake Kate Middleton getting ‘the jab’ from a doc with 1) no gloves on. Mazzalla, who is currently working on COVID-19 vaccine trials, added that it was also wrong to say the needle has a safety cap. It should be noted that COVID-19 vaccine solutions are transparent and the dose is miniscule, measuring less than one millilitre. The Duchess of Cambridge has received a COVID-19 vaccine.
Persons: Duchess, Cambridge’s, Kate, Kate Middleton, , Andrea Mazzella, Mazzalla, BioNTech, Nancy Pelosi, Read Organizations: London’s Science Museum, Reuters, World Health Organisation, WHO, Pfizer, Oxford, AstraZeneca, Moderna, US Locations: Cambridge
AstraZeneca Covid-19 Antibody Treatment Suffers Setback
  + stars: | 2021-06-15 | by ( Jenny Strasburg | ) www.wsj.com sentiment -0.99   time to read: +2 min
AstraZeneca PLC’s coronavirus antibody treatment failed in late-stage clinical trials to achieve its primary goal of preventing symptomatic Covid-19 in people recently exposed to the virus, the latest disappointment in a broader search for reliable post-infection therapies. A single dose of the AZD7442 long-acting antibody treatment wasn’t statistically more effective than a placebo in preventing symptomatic Covid-19 in the trial of 1,121 people in the U.K. and U.S., AstraZeneca said Tuesday. The antibody treatment is separate from AstraZeneca’s widely used Covid-19 vaccine developed in partnership with the University of Oxford. The trial failure is a major setback for hopes by AstraZeneca and the U.S. of using the drug to treat individuals infected with Covid-19. Though the primary goal was preventing symptomatic Covid-19 after confirmed exposure with an infected person, the company said the treatment could find use in people who aren’t well protected by the range of Covid-19 vaccines, or who are unable or unwilling to take a vaccine.
Persons: drugmaker Organizations: AstraZeneca, University of Oxford, U.S
MORNING BID-No taper trauma in sight
  + stars: | 2021-06-15 | by ( Reuters Staff | ) www.reuters.com + 0.00   time to read: +3 min
Pre-Fed price action would suggest markets aren’t anticipating any big trauma from policy normalisation at the world’s leading central bank. JP Morgan said the upcoming tapering process was unlikely to hurt its bullish view on equities for the second half of 2021. It expects the Fed to start tapering early next year. Meantime in Japan a former Bank of Japan policymaker said the bank must eventually consider ways to unload its huge holdings of exchange-traded funds after tapering bond and ETF purchases. Finally, bitcoin steadied after climbing above the $40,000 mark following remarks from Elon Musk who said Tesla may resume allowing Bitcoin transactions.
Persons: Danilo Masoni, pare, JP Morgan, Lagarde, Bank of Japan policymaker, bitcoin, Elon Musk, Tesla, Philip Lane, Fabio Panetta, Andrea Enria, Andrew Bailey Organizations: Fed, Bank of, Boeing, Airbus, Pfizer, AstraZeneca, hospitalisation Locations: Europe, Asia Pacific, Australia, Japan, Bank of Japan, U.S
Brazil's Bolsonaro asks Pfizer to speed up COVID vaccine delivery
  + stars: | 2021-06-15 | by ( ) www.reuters.com sentiment -0.92   time to read: +2 min
Brazil's President Jair Bolsonaro reacts during a ceremony of signing the Vaccine Technology Transfer Agreement for Oxford/AstraZeneca coronavirus disease (COVID-19) vaccines, in Brasilia, Brazil, June 1, 2021. REUTERS/Ueslei MarcelinoBrazilian President Jair Bolsonaro on Monday asked Pfizer Inc (PFE.N) to bring forward planned delivery of COVID-19 vaccines, a government source said, aiming to speed up a slow national inoculation program. The commission heard testimony that the government never replied to letters from Pfizer last year offering to sell vaccines. read moreBrazil signed a deal with Pfizer in March to purchase 100 million doses, and the first doses arrived in late April. A second contract in May provided for another 100 million doses to be delivered in the fourth quarter.
Persons: Jair Bolsonaro, Ueslei Marcelino, Bolsonaro, Marta Diez, Carlos Murillo Organizations: Oxford, AstraZeneca, REUTERS, Monday, Pfizer Inc, Pfizer, Pfizer Brasil, Reuters, China's Sinovac Biotech, AstraZeneca Plc, Thomson Locations: Brasilia, Brazil, COVID
Japan to ship 1 mln COVID-19 vaccines to Vietnam on June 16
  + stars: | 2021-06-15 | by ( ) www.reuters.com sentiment -0.98   time to read: 1 min
A vial labelled with the AstraZeneca coronavirus disease (COVID-19) vaccine is seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File PhotoJapan will send 1 million COVID-19 vaccine doses to Vietnam, Japanese Foreign Minister Toshimitsu Motegi said on Tuesday. The shipment of AstraZeneca PLC (AZN.L) vaccines produced in Japan are due to arrive in Vietnam on Wednesday, Motegi told reporters. Japan is considering additional vaccine donations to Vietnam and Taiwan, and it plans to send doses to Indonesia, Malaysia, the Philippines and Thailand early next month, Motegi added. Taiwan received its first shipment of AstraZeneca doses earlier this month.
Persons: Dado Ruvic, Toshimitsu Motegi, Motegi Organizations: AstraZeneca, REUTERS, Japanese, AstraZeneca PLC, Thomson Locations: Japan, Vietnam, Taiwan, Indonesia, Malaysia, Philippines, Thailand
REUTERS/Dado Ruvic/Illustration/File PhotoAnglo-Swedish drugmaker AstraZeneca (AZN.L) said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the novel coronavirus. AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to a placebo, which was not statistically significant, the company reported. AstraZeneca is also studying the treatment in a pre-exposed patients trial and for preventing more severe disease. The monoclonal antibody therapy belongs to a class of drugs which mimic natural antibodies the body produces to fight off the infection. Rivals Regeneron Pharmaceuticals Inc (REGN.O) and Eli Lilly & Co (LLY.N) have both developed monoclonal antibody therapies which have been authorised for use in the United States to treat patients infected with the virus.
Persons: Dado Ruvic, AZD7442, Eli Lilly Organizations: Astra, AstraZeneca, REUTERS, Rivals Regeneron Pharmaceuticals Inc, European Medicines Agency, GlaxoSmithKline, Vir Biotechnology Inc, Lonza, U.S ., U.S, Thomson Locations: Swedish, United States, Celltrion, Swiss, Portsmouth , New Hampshire
Risk of hospitalization is 85% higher with the Delta variant, new data from the UK shows. But both were less protective against the Delta variant, which is 60% more infectious. The Delta variant of the coronavirus is linked to an 85% higher risk of hospitalization, according to a new study from part of the UK. It is 60% more transmissible than the variant Alpha (B.1.1.7, first seen in the UK), which had been dominant in the UK but was fast supplanted by the Delta variant. The researchers looked at 19,543 confirmed infections, a little fewer than half of which were the Delta variant.
Persons: Boris Johnson, Antony Fauci Organizations: Pfizer, AstraZeneca, White House, Public Health, University of Edinburgh, Alpha Locations: Scotland, India, Public Health England, EAVE
Ping Identity (PING) – Ping Identity announced a 6 million share common stock offering, in a sale of shares held by investment funds affiliated with Vista Equity Partners. The identity management solutions company will not receive any proceeds from the offering. Sage Therapeutics (SAGE) – The drugmaker's shares tanked 17.5% in premarket trading following the release of study results for Sage's experimental depression drug. Citi upgraded the stock to "buy" from "neutral" following that update, and shares rallied 2.6% in the premarket. Novavax (NVAX) – Novavax announced positive results from its first study of its Covid-19 vaccine and a flu vaccine administered simultaneously.
Persons: – Vroom, Ping, Katherine Tai, Morgan Stanley, – AstraZeneca, – Novavax Organizations: Ping Identity, Vista Equity Partners, Sage Therapeutics, Boeing, European Union, Airbus, World Trade Organization, U.S . Trade, Exxon Mobil, – Bank of America, Spirit Airlines, Securities and Exchange Commission, Citi, AstraZeneca, Intuit, SEC, Vimeo Locations: U.S
Astra antibody cocktail fails to prevent Covid-19 symptoms in large trial
  + stars: | 2021-06-15 | by ( ) www.cnbc.com sentiment -0.99   time to read: +1 min
The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing Covid-19 symptoms. The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial. Five more trials are ongoing, testing the antibody cocktail as treatment or in prevention. The next one will likely be from a larger trial testing the product in people with a weakened immune system due to cancer or an organ transplant, who may not benefit from a vaccine.
Persons: AstraZeneca, Mene Pangalos Organizations: AstraZeneca Locations: United Kingdom, United States
How UK PM Johnson decided to delay COVID reopening
  + stars: | 2021-06-15 | by ( Alistair Smout | ) www.reuters.com + 0.00   time to read: +4 min
Models commissioned by the government showed that without a delay to the planned June 21 reopening, in some scenarios hospitalisations could match previous peaks in cases when ministers feared the health system could be overwhelmed. All three found that a delay would lower the peak of a new wave fuelled by the Delta variant. SPI-M-O will make fresh projections before July 19 when the full reopening is now expected to take place, with Johnson saying that he does not want to delay reopening again. The modellers warned that while protection from vaccines was not perfect, without them, England would be heading back into lockdown. Kevin McConway, emeritus professor of applied statistics at The Open University, said the delay would buy time to learn more about the Delta variant, and get more shots in arms.
Persons: Boris Johnson, Johnson, Anne Cori, Cori, Steve Baker, Kevin McConway, Alistair Smout, Josephine Mason, Alison Williams Organizations: Reuters, British, WHO, London School of Hygiene, Medicine, Imperial College London, University of Warwick, Public Health, Pfizer, AstraZeneca, hospitalisation, The Open University, Thomson Locations: England, Britain, Public Health England, India
It said the extended gap was recommended by the National Technical Advisory Group on Immunisation (NTAGI), based on real-life evidence mainly from Britain. But he added that the group had no data concerning the effects of a gap beyond 12 weeks. The health ministry, citing the head of NTAGI's working group on COVID-19, said that the dosing decision was based on scientific evidence. Government health officials told a news conference on May 15 the gap was not increased to address a vaccine shortage but was a "scientific decision". The AstraZeneca vaccine accounts for nearly 90% of the 257.5 million vaccine doses administered in India.
Persons: Dinuka, M.D, Mathew Varghese, NTAGI's, Arora, Muliyil, Shahid Jameel, Krishna N, Devjyot, Sanjeev Miglani Organizations: Serum Institute of India, Infectious Diseases, REUTERS, Indian, AstraZeneca, Reuters, National Technical Advisory, National, of Epidemiology, World Health Organization, Twitter, Pfizer, New, Das, Thomson Locations: Colombo, Sri Lanka, DELHI, Britain, South Korea, India, Indian, New Delhi
Full coverage of the coronavirus outbreakThe new analysis found that two doses of the Pfizer vaccine were 96 percent effective against hospitalization from the Delta variant, and two doses of the AstraZeneca vaccine were 92 percent effective. Pfizer CEO Albert Bourla expressed confidence about how the Pfizer vaccine fared against the Delta variant on “CBS This Morning” on Monday. For example, a real-world study found the Pfizer vaccine to be highly effective against the Alpha variant in Qatar. Still, public health officials remain concerned about the Delta variant. Based on what has happened in other countries, Poland said that he suspects the Delta variant will become dominant in the United States in the fall.
Persons: PHE, , Paul Offit, , Gregory Poland, Dr, Mary Ramsay, Angela Rasmussen, Albert Bourla, ” Rasmussen, “ We've, ” PHE, Rasmussen Organizations: Pfizer, AstraZeneca, Public Health, Children's Hospital of Philadelphia, Vaccine Research, University of Saskatchewan’s, Infectious Disease Organization, CBS, NBC, Alpha, Twitter, Facebook Locations: India, United Kingdom, England, , Mayo, Rochester , Minnesota, Qatar, Poland, United States
WTO head says pandemic-related trade barriers are rising
  + stars: | 2021-06-14 | by ( Emma Farge | ) www.reuters.com sentiment -1.00   time to read: +2 min
REUTERS/Dado Ruvic/Illustration/File PhotoThe head of the World Trade Organization said on Monday that trade barriers related to medical supplies used against COVID-19 had risen and urged member states to drop them, as it intensified efforts to reach a deal on vaccine-sharing. "The trend is going in the wrong direction," WTO Director General Ngozi Okonjo-Iweala told a virtual U.N. forum, referring to barriers on goods trade related to the pandemic. "We need to bring those restrictions down so we can move ... medical goods and supplies and vaccines (faster)." One such measure is the European Union's export authorisation scheme for COVID-19 vaccines, which is set to expire on 30 June. Most developing countries support the waiver but several wealthy countries remain strongly opposed, saying it will deter research that allowed COVID-19 vaccines to be produced so quickly.
Persons: Johnson, Dado Ruvic, Ngozi Okonjo, Iweala Organizations: AstraZeneca, Pfizer, Biontech, Sputnik, REUTERS, World Trade Organization, WTO, International Chamber of Commerce, Thomson Locations: European, Okonjo
Novavax Covid-19 Vaccine Is 90% Effective in Key Study
  + stars: | 2021-06-14 | by ( Peter Loftus | ) www.wsj.com + 0.00   time to read: +10 min
Despite the study results, Novavax said it needs much of that time to ensure that its manufacturing processes meet regulatory standards. Novavax started its late-stage, or Phase 3, trial of the Covid-19 vaccine in late December. Novavax said that the vaccine was 93.2% effective combined against the variants of concern and variants of interest in the study. One challenge conducting the study, Novavax said, was the availability of authorized vaccines. In all, about 5,000 people dropped out of the study, Novavax said, meaning the Covid-19 cases that were used to determine efficacy occurred among the remaining 25,000 study subjects, Dr. Glenn said.
Persons: Novavax, , Gregory Glenn, T.J, Kirkpatrick, Stanley Erck, Erck, Biden, Johnson, wasn’t, Glenn, Peter Loftus Organizations: Novavax Inc, Wall, Health, U.S . Food, Drug Administration, Pfizer Inc, Moderna Inc, Pfizer, BioNTech, Moderna, FDA, D.C, GlaxoSmithKline, Johnson, AstraZeneca, National Institutes of Health, peter.loftus Locations: U.S, Mexico, Gaithersburg, Md, China, Covid, Washington, Chile, Brazil, India
Public health officials in the U.K. say they are increasingly confident that vaccines offer significant protection against the Delta variant of coronavirus, a hopeful sign as the highly transmissible strain spreads across the world. Separate studies from researchers in England and Scotland published Monday found that while protection against infection was somewhat diminished against Delta compared with more established variants, two doses of vaccine offered considerable protection against severe illness and hospitalization. The findings are the latest indicating that Covid-19 vaccines are able to protect people against new variants, despite early concerns that the variants might be able to elude them. An analysis of more than 14,000 Delta cases by England’s public health agency found a double dose of the shot developed by Pfizer Inc. and BioNTech SE reduces the risk of hospitalization after infection with Delta by 96%. Two doses of the vaccine developed by the University of Oxford and AstraZeneca reduces the risk by 92%, Public Health England said.
Persons: , Aziz Sheikh Organizations: Delta, University of Edinburgh’s, Institute of, Pfizer Inc, University of Oxford, AstraZeneca, Public Health Locations: England
UK's Boris Johnson to extend Covid-19 restrictions in England, reports say
  + stars: | 2021-06-14 | by ( Elliot Smith | ) www.cnbc.com sentiment -1.00   time to read: +1 min
Boris Johnson is expected to announce a delay to the next phase of England's reopening of up to four weeks on Monday, amid a surge in the delta variant of Covid-19 first discovered in India. People will also be advised to continue working from home where possible, according to reports. More than 70 million vaccine doses have been administered across the U.K., with around 80% of the country having now received at least one dose. But a PHE paper in late May showed that the Pfizer and AstraZeneca vaccines were only 33% effective against the delta variant after a single shot. Johnson told Sky News on Saturday that he was prepared to be "cautious" in order to avoid any future reintroduction of lockdown measures.
Persons: Boris Johnson, Johnson Organizations: Public Health, Pfizer, AstraZeneca, Sky News Locations: India
A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. Additionally, the two-dose vaccine was found to be 100% effective in preventing moderate and severe disease and 93% effective against some variants, Novavax said. The new data comes as federal officials say the U.S. has more than enough doses of Covid vaccines to finish vaccinating the entire American population. It's possible the U.S. could end up donating doses of the Novavax vaccine. Novavax said Monday it remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the fourth quarter of 2021.
Persons: Novavax, Dr, Gregory Glenn, Johnson, Biden Organizations: Biotech, Food and Drug Administration, Alpha, FDA, Pfizer, BioNTech, Moderna, Johnson, Centers for Disease Control, U.S, White House, Defense, AstraZeneca, Sanofi, Novavax Locations: United States, Mexico, U.S
WTO head hopes for deal by July on vaccine-sharing
  + stars: | 2021-06-14 | by ( ) www.reuters.com sentiment -1.00   time to read: 1 min
Vials labelled "AstraZeneca, Pfizer - Biontech, Johnson&Johnson, Sputnik V coronavirus disease (COVID-19) vaccine" are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic/Illustration/File PhotoThe head of the World Trade Organization said on Monday she hoped that members could reach an agreement by July on improving access to COVID-19 vaccines after months of talks on waiving drug firms' intellectual property rights. "It's going to be tough because there are still differences but we hope we can get to a pragmatic approach," Ngozi Okonjo-Iweala told a virtual U.N. forum. "I'm in a hurry and I want us to get some agreement by July because lives are important." Our Standards: The Thomson Reuters Trust Principles.
Persons: Johnson, Dado Ruvic, Iweala Organizations: AstraZeneca, Pfizer, Biontech, Sputnik, REUTERS, World Trade Organization, Thomson
Novavax said its coronavirus vaccine was 90% effective at preventing COVID-19. The biotech company Novavax said on Monday that its coronavirus vaccine succeeded in a final-stage clinical trial, demonstrating 90% efficacy at preventing COVID-19. It remains to be seen how the Novavax vaccine will be used in the US immunization campaign. Among the most vulnerable population — including older people and those with frequent exposure to the virus — Novavax's vaccine was 91% effective. Despite the uncertainty surrounding its use in the US, Novavax's COVID-19 vaccine program has been a remarkable and unlikely success story.
Persons: Novavax, Stanley Erck, Johnson, AstraZeneca's, Read, Rhonda Flores, Andrew Caballero, Reynolds, Novavax's, Bill Gates Organizations: Moderna, Pfizer, BioNTech, Centers for Disease Control, pharma, US Food and Drug Administration, AFP, Coalition for Locations: COVID, Mexico, Maryland, South Africa, Gaithersburg , Maryland
Doctors in India say COVID-19 patients have unusual symptoms that could be due to the Delta variant. Doctors in India claim that the highly infectious Delta variant could cause unusual symptoms such as gangrene and hearing loss, which they say are becoming more common in COVID-19 patients of all ages. The highly infectious variant has spread to 67 countries and is becoming more common around the world. The Delta variant is estimated to be 60% more infectious than the Alpha variant that's currently the most common in the US. A Public Health England document from May reported the Pfizer and AstraZeneca vaccines were respectively 88% and 60% effective against the Delta variant after both doses.
Persons: Anthony Fauci, Joe Biden's, didn't, Ganesh Manudhane, Manudhane, Dr, Abdul Ghafur, hadn't, Anurag Agarwal, Agarwal, Neil Ferguson, Dr Jeffery Barrett, Barrett, Pradeep Gaur, Harsh Vardhan, it's, Ghafur, Shailesh Kothalkar, David Denning Organizations: Bloomberg, Daily Mail, Alpha, Health, Pfizer, AstraZeneca, Delta, Seven Hills, Apollo Hospital, Indian, of Medical Research, of Genomics, MRC Centre, Infectious, Imperial College London, Genomics, Wellcome Sanger Institute, Rapid, Getty, Seven Star Hospital, Telegraph, University of Manchester, Global, Fund, Fungal Infections Locations: India, COVID, Mumbai, Chennai, Nature, Delhi, New Delhi, Nagpur
England’s delayed reopening is expected to have a ‘minor’ economic impact.
  + stars: | 2021-06-14 | by ( Eshe Nelson | ) www.nytimes.com sentiment -0.99   time to read: +1 min
“If a delay materializes as reported, we think the economic significance should be minimal,” analysts at UBS wrote. That month, the economy grew 2.3 percent from the previous month, and was just 3.7 percent smaller than it was before the pandemic. As businesses have learned to adapt to restrictions — for example, as more restaurants have begun offering takeout service — the economic impact of each lockdown has been smaller. The third phase of the reopening has a smaller economic impact than the first two, “so even if it is postponed it shouldn’t have a major impact on the outlook,” analysts at RBC Capital Markets wrote. UKHospitality said the prospects for many businesses were “grim” and urged the government not to delay reopening.
Persons: UKHospitality Organizations: UBS, Pfizer, AstraZeneca, RBC Capital Markets, Time Industries Association
Check out the companies making headlines before the bell:Novavax (NVAX) – The drugmaker said its Covid-19 vaccine proved 90% effective overall in a late-stage trial, and 93% effective against the most predominant variants of the virus. Phillips (PHG) – Phillips shares slid 4.3% in premarket action after saying it would recall up to 4 million CPAP machines due to potential toxicity risks. Chipotle shares gained 1.4% in the premarket. Shares gained 2% in premarket trading. NextGen shares gained 1.9% in the premarket.
Persons: Steve Burns, Julio Rodriguez, Lordstown, Burns, Rodriguez, Phillips, – Phillips, – Raymond James, Ferrari, – Goldman Sachs, Marco Cavaleri, Oatly, Oppenheimer, Morgan Stanley, Piper Sandler, Jefferies, JPMorgan Chase, Cristiano Amon, Equinix, – Equinix, Sir Richard Branson's Virgin, Sky, NextGen Organizations: Lordstown Motors, Grill, GlaxoSmithKline, GSK, iTeos Therapeutics, AstraZeneca, European Medicines, Royal, Shell, Reuters, Credit Suisse, Guggenheim, JPMorgan, RBC, Qualcomm, Nvidia, Sir Richard Branson's Virgin Orbit, Sky News, Virgin Locations: Texas
But private hospitals will still charge for vaccines, and it is unclear whether the government has enough stock of free vaccines. Private hospitals will continue charging for the vaccine, and the supply at government hospitals — where the vaccine is free — has been tragically low so far. From the start, India's vaccine drive has been terribly mismanaged, costing thousands of Indians their lives. Some of them could have been saved if the vaccine drive was better managed. Modi basically announced the second phase of the biggest vaccine drive in the world while knowing there wasn't sufficient stock available.
Persons: Modi, Peony, Narendra Modi, haven't, It's, Dinesh Ramkumar, Bharat, Covaxin Organizations: Covishield, AstraZeneca, US Food and Drug Administration Locations: India, , Rajasthan
Total: 25